



## UCB signs a new EUR 1.5 billion credit facility

**Brussels, Belgium, December 15 2009 – 8:30 (CET). Regulated information.** - UCB SA ("UCB" or the "Company") is pleased to announce the signing of its new EUR 1.5 billion revolving credit facility.

The purpose of the facility is to refinance the Company's EUR 4 billion banking facility arranged in connection with the 2006 acquisition of Schwarz Pharma, which has since amortised to EUR 3.3 billion and is due to mature in October 2011.

The new facility has a three year maturity and a one year extension option.

The margin and other terms and conditions are customary for similar investment grade loan facilities.

Prior to arranging this new facility, UCB has successfully issued three bonds with different maturities raising EUR 1.75 billion in total from debt capital markets. The proceeds from these bonds will also be used to refinance the existing credit facility.

Detlef Thielgen, Chief Financial Officer of UCB, commented, "We are very pleased to have successfully completed this new facility. It is the next step in our strategy to firmly establish UCB as a global biopharma industry leader. The fact that all banks originally invited into this transaction have signed up to the agreement, underscores the confidence which the loan and debt capital markets have shown in UCB throughout this refinancing process."

### **For further information**

*Richard Simpson, Investor Relations, UCB*  
T +32.2.559.9494, [richard.simpson@ucb.com](mailto:richard.simpson@ucb.com)

*Michael Tuck-Sherman, Investor Relations, UCB*  
T +32.2.559.9712, [michael.tuck-sherman@ucb.com](mailto:michael.tuck-sherman@ucb.com)

*Nancy Nackaerts, External Communications, UCB*  
T +32.473.864.414, [nancy.nackaerts@ucb.com](mailto:nancy.nackaerts@ucb.com)

### **About UCB**

*UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10 000 people in over 40 countries, UCB generated revenue of 3.6 billion euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).*

### **Forward looking statement**

*This press release contains forward-looking statements based on current plans, estimates and*



*beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.*